Incyte And Syndax Present Additional Data From Positive AGAVE-201 Trial At ASH Plenary Session Showing Axatilimab Efficacy
Portfolio Pulse from Benzinga Newsdesk
Incyte and Syndax Pharmaceuticals announced positive results from the AGAVE-201 trial of axatilimab for treating chronic GVHD, with a 74% response rate at the 0.3 mg/kg dose. The data were presented at the ASH Annual Meeting 2023. They plan to file a BLA for axatilimab by the end of 2023.
December 11, 2023 | 7:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Incyte's positive trial results for axatilimab and upcoming BLA filing could boost investor confidence and potentially increase stock value in the short term.
Positive clinical trial results typically lead to increased investor optimism, especially when they are presented at prestigious conferences like ASH. The announcement of a planned BLA filing indicates regulatory progress, which can further drive positive sentiment.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Syndax Pharmaceuticals' involvement in the successful AGAVE-201 trial and the anticipated BLA filing for axatilimab may positively influence its stock price in the short term.
As a partner in the development of axatilimab, Syndax stands to benefit from the positive trial outcomes. The presentation of data at a major conference and the planned BLA filing are significant milestones that can attract investor interest and potentially drive up the stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80